DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated at Craig Hallum

Investment analysts at Craig Hallum initiated coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective would indicate a potential upside of 216.21% from the company’s previous close.

Separately, Oppenheimer restated an “outperform” rating and set a $6.00 price target (down previously from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC opened at $2.53 on Wednesday. The company’s 50 day simple moving average is $2.80 and its 200 day simple moving average is $2.69. DiaMedica Therapeutics has a 12 month low of $1.53 and a 12 month high of $4.75. The company has a market capitalization of $96.03 million, a P/E ratio of -4.08 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, analysts anticipate that DiaMedica Therapeutics will post -0.69 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stonebridge Capital Advisors LLC purchased a new position in DiaMedica Therapeutics during the third quarter valued at approximately $52,000. Paragon Associates & Paragon Associates II Joint Venture grew its position in DiaMedica Therapeutics by 6.4% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Avantax Advisory Services Inc. purchased a new position in DiaMedica Therapeutics during the fourth quarter valued at approximately $36,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.